IAG Launches DYNAMIKA 7: A Game-Changer in Imaging Clinical Trials

DYNAMIKA: Powerful Solution for Clinical Trial Imaging

DYNAMIKA is Image Analysis Group’s proprietary, cloud‑native platform for managing, reviewing, and analyzing imaging data in clinical trials, built to support biopharma from early phase through post‑marketing studies. It evolved from IAG’s roots as an imaging CRO founded in 2007, where the team initially developed in‑house tools to objectively quantify MRI and other imaging data for inflammatory and musculoskeletal indications, then generalized those tools into a configurable platform.

Over time, IAG moved DYNAMIKA fully into the cloud (already in use that way by around 2011), which was early for clinical imaging and required solving for privacy, data residency, and sponsor concerns about remote image access. The platform has since grown into an enterprise workflow solution that centralizes image collection, automated anonymization and QC, site and reader performance tracking, and centralized image review with built‑in eCRFs and audit trails.

Technically, DYNAMIKA is built as a cloud‑native, AI‑ready infrastructure that integrates advanced analytics and embedded AI tools, enabling automated, quantitative image analysis and AI‑powered endpoints across oncology, immunology, neurology, rare diseases, and more.

The IAG team and its partners develop imaging biomarkers and AI models, then deploy them inside DYNAMIKA so they can be used consistently across global studies, including for real‑world evidence and AI powered projects.

Launch of DYNAMIKA V7

The launch of DYNAMIKA V7 marks a defining moment for Image Analysis Group and for how imaging is used in drug development. This is no incremental upgrade; it is a statement of intent that imaging data must be as robust, trusted, and strategic as any other core clinical asset. With British Standards Institute (BSI) surveillance audit certification on top of fresh SOC II Type I compliance, DYNAMIKA V7 stands as a platform sponsors can rely on when the stakes are highest—late‑stage trials, pivotal readouts, and regulatory scrutiny.

Being named the Award Category Winner for Innovation in the 2024 Pharmaceutical Technology Excellence Awards reinforces what many in the industry have already felt in practice: DYNAMIKA is not just “another” imaging tool, but a proprietary technology stack built to transform how imaging evidence is generated, curated, and deployed across portfolios. That recognition is powerful because it links innovation to impact—acknowledging that the platform can genuinely change the trajectory of clinical programs, especially in oncology, immunology, and rare diseases where imaging endpoints are central.

DYNAMIKA V7 arrives at exactly the right time. Clinical trials are more complex than ever, with adaptive designs, biomarker‑driven cohorts, and integrated RWE components all raising the bar on data quality and speed. In this environment, imaging can no longer lag behind as a slow, manual, fragmented process. DYNAMIKA 7 was engineered to flip that script: to bring unmatched precision in quantification, dramatic gains in turnaround time, and real operational agility—so that imaging actually accelerates development instead of holding it back.

For biotech and pharma partners, this means more than cleaner dashboards or nicer viewers. It means having a platform that can ingest global imaging data at scale, centralize QC and reads, deploy AI‑powered analytics, and feed high‑confidence endpoints directly into critical decisions—dose, indication, patient selection, go/no‑go, and regulatory interactions. It turns each scan into actionable evidence that helps differentiate a mechanism, de‑risk a safety profile, and strengthen the value story of a clinical‑stage asset.

DYNAMIKA V7 is, in many ways, the culmination of years of scientific ambition and engineering discipline at Image Analysis Group: a cloud‑native, compliant, award‑winning platform designed not just to keep pace with modern clinical trials, but to help lead where imaging goes next.

Impact

“With DYNAMIKA 7, we are empowering our partners to reimagine what’s possible in imaging clinical trials. The platform is more than a technology—it’s a strategic enabler that reduces uncertainty, accelerates timelines, and brings clarity to complex data. This release reflects our commitment to innovation, collaboration, and the ultimate goal of delivering life-changing therapies to patients faster,” said Dr. Olga Kubassova, CEO and Founder of Image Analysis Group.

Key highlights of DYNAMIKA 7 include:

• Next-generation analytics powered by advanced AI algorithms, delivering deeper insights into disease progression and treatment response.
• Enhanced scalability and performance, enabling robust data logistics of large datasets in global, multi-center trials.
• Streamlined regulatory compliance, with new reporting capabilities, the data generated in trials supports FDA, EMA, and global submissions.
• User-centered design, offering an intuitive interface for clinical teams to review, collaborate, and make data-driven decisions quickly.

AI Power in DYNAMIKA

With artificial intelligence becoming an essential driver of business success, IAG aims to bridge the gap between innovation and usability of clinical trial imaging platforms. Designed for a variety of trial scenarios such as collect and hold, umbrealla and basket trials, RWE, and more, DYNAMIKA platform delivers scalable infrastructure and relibale data workflows that redefine efficiency.

The launch of DYNAMIKA 7 and IAG’s Partnerships network marks just the beginning of an exciting journey. IAG team is committed to continuous innovation, with new features and capabilities in the technical pipeline, driven by customer feedback and emerging industry trends.

“We are not just introducing another tool—we are shaping the future of clinical trial imaging,” Jon Himoff added. “IAG empowers companies to work smarter, adapt faster, and achieve success beyond expectations.”

About Image Analysis Group (IAG)

Image Analysis Group is a science-driven partner to biotech and pharma companies, specializing in the use of innovative imaging, AI, and advanced analytics to transform clinical development. With a unique combination of deep therapeutic expertise and cutting-edge technology, IAG helps sponsors de-risk drug development, accelerate clinical timelines, and deliver meaningful outcomes for patients.